The process of switching from long-acting insulin, such as Lantus (insulin glargine), to a premixed insulin formulation like 70/30 (a combination of 70% intermediate-acting NPH insulin and 30% rapid-acting regular insulin) necessitates careful calculation. This calculation is critical for maintaining adequate glycemic control during the transition. The calculation aims to determine the appropriate initial dose of the 70/30 insulin based on the individual’s previous Lantus dosage. For example, if an individual was previously taking 40 units of Lantus daily, the calculated equivalent dose of 70/30, distributed across multiple injections, might be lower than the Lantus dose due to the differing pharmacokinetic profiles of the insulin types.
Accurate conversion from one insulin regimen to another is vital to minimize the risks of both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar). Prior to combination insulins, individuals relied solely on long acting alternatives for basal coverage. Now, premixed insulin offers a simplified approach for some patients, reducing the number of daily injections. The appropriate dosage adjustment is paramount, especially considering that 70/30 insulin provides both basal and bolus coverage in a fixed ratio, unlike Lantus, which provides basal coverage alone. Consequently, it is crucial to account for the individual’s carbohydrate intake and activity levels when determining the optimal 70/30 dosage.
